Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank28
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P28
Within normal range
vs 3Y Ago
-0.7x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -5.67% |
| Q3 2025 | 5.50% |
| Q2 2025 | -0.13% |
| Q1 2025 | -1.90% |
| Q4 2024 | 14.02% |
| Q3 2024 | -83.83% |
| Q2 2024 | 525.44% |
| Q1 2024 | -35.94% |
| Q4 2023 | 56.86% |
| Q3 2023 | -3.85% |
| Q2 2023 | 20.68% |
| Q1 2023 | 6.99% |
| Q4 2022 | 7.61% |
| Q3 2022 | 7.48% |
| Q2 2022 | -0.50% |
| Q1 2022 | -13.14% |
| Q4 2021 | 40.62% |
| Q3 2021 | -64.91% |
| Q2 2021 | 208.59% |
| Q1 2021 | -2.27% |
| Q4 2020 | -5.45% |
| Q3 2020 | 17.24% |
| Q2 2020 | -6.15% |
| Q1 2020 | -6.56% |
| Q4 2019 | -13.66% |
| Q3 2019 | 46.65% |
| Q2 2019 | 11.66% |
| Q1 2019 | -22.47% |
| Q4 2018 | 32.49% |
| Q3 2018 | -2.08% |
| Q2 2018 | 8.69% |
| Q1 2018 | 1.27% |
| Q4 2017 | -32.59% |
| Q3 2017 | 57.18% |
| Q2 2017 | 5.81% |
| Q1 2017 | 10.11% |
| Q4 2016 | -9.78% |
| Q3 2016 | 1.61% |
| Q2 2016 | 5.92% |
| Q1 2016 | -17.58% |